ChromaTan Wins NIH Phase 1 SBIR

We are very excited to announce that ChromaTan (APV portfolio company) and their team of scientists have recently been awarded an NIH SBIR Phase 1 for $183,000. Their proposal focuses on: design, construction, and testing a Continuous Countercurrent Tangential Chromatography (CCTC) system capable of providing highly efficient and low cost purification of therapeutic proteins and vaccines.

view article here

view another ChromaTan article